Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP-DC vs OC-DC Vaccines in Advanced HGSOC
NCT05714306Phase 2Withdrawn
- Sponsor
- Lausanne University Hospital
- Start
- Aug 2023
- Primary completion
- Mar 2030
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
A Phase 2 trial of PEP-DC, OC-DC in high grade serous ovarian carcinoma (HGSC), sponsored by Lausanne University Hospital. Planned start Aug 2023; status: withdrawn.
02
Drugs
PEP-DCOC-DC
03
Conditions
high grade serous ovarian carcinoma (HGSC)
Beyond the preview
Go deeper on NCT05714306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05714306.